

Characteristics and outcomes of inflammatory bowel disease patients: an open, multinational OHDSI network study

PRESENTER: **Chen Yanover**
KI Research Institute

INTRO

- Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases with consistently increasing incidence rates
- These conditions significantly impact the quality of life of patients and families

METHODS

Study design. A multinational cohort study using routinely collected healthcare data.

Data sources.

- IQVIA Medical Research Data, primary care electronic health records (EHRs) from the United Kingdom (**IMRD-UK**, version: 2019-03); over 12.5 million patients, approximately 5% of the UK population
- The Ajou University School of Medicine (**AUSOM**) data, an EHR database from Ajou university hospital in South Korea, containing >2.8 million patients, from 1995 to 2022

Study population. IBD cohorts include individuals with at least two diagnoses of IBD or with an IBD diagnosis and a prescription for an IBD medication; CD and UC cohorts further require at least one diagnosis of the corresponding disease and none of the other

Characteristics and outcomes.

- Baseline characteristics: during patients' entire history, 1Y, 1M before index date
- Outcomes and treatments: during the 1M, 1Y, 3Y, 5Y, 10Y, following index date and full follow-up time window
- Attributes: OHDSI predefined features (demographics, condition groups, drug era groups), +100 IBD-specific features

A unified, global characterization of INFLAMMATORY BOWEL DISEASE patient cohorts



Setting the stage for IBD-related predictive and estimation OHDSI network studies

... download analysis package



Scan QR to



... read study protocol



... explore full results



	Crohn's disease		Ulcerative colitis	
	AUSOM	IMRD-UK	AUSOM	IMRD-UK
n	402	6,936	635	13,924
Females	36.6%	54.4%	36.2%	49.1%
Age				
<20 years	25.9%	16.3%	7.9%	5.8%
20-65 years	67.3%	69.8%	83.2%	71.3%
>65 years	4.7%	13.8%	8.0%	22.8%
BMI category ^a				
Underweight	4.0%	5.6%	1.9%	2.7%
Normal	12.7%	31.5%	15.7%	29.3%
Overweight	4.0%	25.8%	5.0%	30.2%
Obese	-	17.4%	-	18.5%
Medications (index date - 30 days)				
5-ASA	65.9%	43.2%	84.4%	67.0%
Immunomodulator	15.4%	8.2%	4.7%	2.0%
Corticosteroids ^b	7.0%	6.2%	5.0%	4.2%
Antibiotics	23.1%	1.1%	9.3%	0.6%
Outcomes (index date - 3 years)				
Anxiety	10.4%	6.7%	13.2%	6.7%
Depression	4.7%	9.3%	5.8%	8.2%
Anemia	5.5%	7.6%	1.7%	6.6%
Procedures (index date - 3 years)				
S bowel resection	4.7%	10.5%	1.1%	4.7%

^a Underweight: BMI <18.5 kg/m², normal weight: 18.5-25 kg/m², overweight: 25-30 kg/m², obese: >30 kg/m².

^b Systemic (prednisone, methylprednisolone) and intestinal locally acting (prednisolone, hydrocortisone, prednisone, betamethasone, tixocortol, budesonide, beclometasone) steroids.

INTERESTED? Join us!



COLLABORATORS



Ajou University

Jimyung Park, Rae Woong Park, Kwang Jae Lee, Sung Jae Shin



Ben-Gurion University

Nadav Rappoport



Rambam Medical Center

Ramit Magen-Rimon, Yehuda Chowers, Roni Weisshof



KI Research Institute

Tal El-Hay, Maytal Bivas-Benita, Pinchas Akiva

